구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | atezolizumab (Tecentriq, Atezolizumab Injection [Tecentriq]) Roche / Genentech·Lung Neoplasm Malignant 2 trials |
|---|---|
Overview Program | Atezolizumab Injection [Tecentriq] |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Lung Neoplasm Malignant |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Toxicology Major finding | Subcutaneous atezolizumab for the treatment of non-small cell lung cancer.. Subcutaneous atezolizumab (with rHuPH20) streamlines anti-PD-L1 delivery while preserving the intravenous (IV) formulation's performance. This review integrates pharmacokinetic, clinical, safety, patient-reported, and operational data from IMscin001 and related studies in NSCLC. A fixed 1,875-mg SC dose every 3 week… |
Toxicology CRS | Reported |
Clinical Safety signal | Subcutaneous atezolizumab for the treatment of non-small cell lung cancer.. Subcutaneous atezolizumab (with rHuPH20) streamlines anti-PD-L1 delivery while preserving the intravenous (IV) formulation's performance. This review integrates pharmacokinetic, clinical, safety, patient-reported, and operational data from IMscin001 and related studies in NSCLC. A fixed 1,875-mg SC dose every 3 week… |
Clinical Program phase | APPROVED |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | atezolizumab (Tecentriq, Atezolizumab Injection [Tecentriq]) Roche / Genentech·Lung Neoplasm Malignant 2 trials |
|---|---|
Overview Program | Atezolizumab Injection [Tecentriq] |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Lung Neoplasm Malignant |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Toxicology Major finding | Subcutaneous atezolizumab for the treatment of non-small cell lung cancer.. Subcutaneous atezolizumab (with rHuPH20) streamlines anti-PD-L1 delivery while preserving the intravenous (IV) formulation's performance. This review integrates pharmacokinetic, clinical, safety, patient-reported, and operational data from IMscin001 and related studies in NSCLC. A fixed 1,875-mg SC dose every 3 week… |
Toxicology CRS | Reported |
Clinical Safety signal | Subcutaneous atezolizumab for the treatment of non-small cell lung cancer.. Subcutaneous atezolizumab (with rHuPH20) streamlines anti-PD-L1 delivery while preserving the intravenous (IV) formulation's performance. This review integrates pharmacokinetic, clinical, safety, patient-reported, and operational data from IMscin001 and related studies in NSCLC. A fixed 1,875-mg SC dose every 3 week… |
Clinical Program phase | APPROVED |
추천 비교
추천 비교